Artificial intelligence not only makes it possible to predict certain pathologies or diseases, saving lives and improving the daily lives of patients and doctors, it goes even further. AI can now be used to develop innovative biologics as part of targeted therapies for patients suffering from cancer and autoimmune diseases. This is the specialization of Chinese nugget Biotheus. New technologies applied to healthcare also affect the dental field, and are now involved in the preparation and administration of drugs and dangerous molecules. Artificial intelligence never ceases to amaze!
Overjet revolutionizes dental care with artificial intelligence
Founded in 2018 by experts from the Massachusetts Institute of Technology (MIT) and the Harvard School of Dental Medicine, Overjet is ranked by Forbes among the world's top 50 artificial intelligence companies.
The American company has developed a technology approved by the FDA, the US agency in charge of protecting public health, capable of analyzing 18 months of X-rays to detect future caries, quantify dental bone loss and identify potential periodontal disease that may not yet have been diagnosed.
The artificial intelligence developed by Overjet ultimately helps streamline diagnostic processes, given that 1/4 of all diagnoses made by dental practitioners are incorrect.
The company's valuation exceeded $425 million in December 2021.
Equashield offers uneven protection for the preparation of hazardous drugs
Also in the USA, Equashield has become one of the world's leading suppliers of manual and automated technologies for the preparation and administration of hazardous drugs and molecules. The Closed System Transfer Device (CSTD) developed by Equashield offers unrivalled safety and ease of use for healthcare workers handling hazardous substances.
CSTDs are transfer devices used to limit the exposure of hazardous and noxious drugs or vapors to the outside environment.
Equashield's CSTD is clinically proven to protect healthcare professionals from exposure to hazardous drugs. The award-winning Equashield II device covers more routes of exposure than alternative systems, preventing contamination from syringe plungers and drug residues on connector surfaces, as well as exposure to drug vapors. Studies have shown that Equashield CSTDs are faster to implement and easier to use than competing systems.
The 400-strong company has also launched Equashield Pro, designed to make advanced automation technologies both affordable and easy to integrate into hospital pharmacies, with a footprint and size comparable to that of a standard biological safety cabinet.
This system enables the rapid preparation of a wide variety of patient-specific chemotherapeutic doses, based on an optimized process flow that performs several tasks simultaneously. Equashield Pro's dose verification software reduces dosing mishaps and misidentification during the preparation of hazardous drugs. Equashield recorded sales of 105 million euros in 2022, up 24% year-on-year.
Biotheus improves targeted therapies for patients with cancer and autoimmune diseases
Heading for China, where Biotheus has perfected cutting-edge monoclonal antibody production technology to develop therapies targeting patients suffering from cancer and autoimmune diseases. Thanks to its research, Biotheus aims to mass-produce innovative biological products to make them accessible to the most disadvantaged populations.
The company has recorded sales of $10 million in 2021
These three international companies are present in the Vintage Altaroc Odyssey 2021.
.webp)
